Vericel Stock Price, News & Analysis

Vericel Corporation (NASDAQ:VCEL) announced its upcoming third-quarter 2020 earnings call scheduled for November 5, 2020, at 8:30 AM EDT. The call will provide a detailed discussion on the company's financial results and business highlights. Interested parties can join the live call via the Vericel website or by phone. Key products include MACI^® for cartilage repair and Epicel^® for severe burns. The company also holds North American rights to NexoBrid^®, aimed at severe thermal burn treatment.

Vericel Corporation (NASDAQ:VCEL) reported preliminary financial results for Q3 2020, with total net revenues of approximately $32 million, including $24.2 million from MACI, $6.7 million from Epicel, and $1.2 million from NexoBrid. The company generated $4.6 million in operating cash flow, holding $85.5 million in cash with no debt. CEO Nick Colangelo expressed optimism for continued growth in MACI, despite uncertainties due to COVID-19. Key investor events are scheduled for October 16 and November 5.

Vericel Corporation (NASDAQ: VCEL) will host a virtual Analyst and Investor Day on October 16, 2020, from 9:00 a.m. to 11:00 a.m. ET. Executives will provide updates on U.S. commercialization plans for NexoBrid, a product aimed at the debridement of severe burns, and discuss its potential impact on current burn treatment practices. The event will feature burn surgeon thought leaders. Interested parties can access the live webcast and a subsequent replay through their investor relations website.

Vericel Corporation (NASDAQ: VCEL) announced on September 16, 2020, that the FDA has accepted its Biologics License Application for NexoBrid® to treat deep partial-thickness and full-thickness thermal burns. The FDA set a PDUFA target date of June 29, 2021, without plans for an advisory committee meeting. CEO Nick Colangelo emphasized the significance of this milestone in establishing a new standard of care for burn treatment, while MediWound's CEO expressed gratitude to partners involved in the development. Vericel will host a virtual Analyst and Investor Day on October 16, 2020, to discuss NexoBrid's potential impact.

Vericel Corporation (NASDAQ: VCEL) announced that Nick Colangelo, its President and CEO, will present at the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020, at 2:45 p.m. ET. The conference will be conducted virtually, and the presentation will be accessible via a live webcast on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, with products like MACI® and Epicel®. The company also holds exclusive North American rights to NexoBrid® for burn treatment.

Vericel Corporation (NASDAQ: VCEL) announced a significant procurement from BARDA of $16.5 million for NexoBrid, aimed at enhancing U.S. preparedness for burn incidents. This initial shipment marks a critical milestone in its partnership with BARDA, with more deliveries planned through 2021. NexoBrid is designed for emergency treatment of severe burns and has been submitted for FDA approval. Vericel and MediWound will split the profits from this procurement, which is part of a long-term contract initiated in 2015 to develop and provide medical countermeasures for mass casualty situations.

Vericel Corporation (NASDAQ: VCEL) announced a conference call to discuss its second-quarter 2020 financial results scheduled for August 5, 2020, at 8:30 am EDT. The call will be accessible via the company’s website and through a telephone line for participants. Vericel specializes in advanced therapies in sports medicine and severe burn care, marketing products such as MACI® and Epicel®. The conference will provide insights into the company’s financial performance and business outlook for the upcoming period.

Vericel Corporation (NASDAQ: VCEL) submitted a Biologics License Application (BLA) to the FDA for NexoBrid^®, aimed at treating adults with thermal burns through eschar removal. The submission is supported by the pivotal Phase 3 DETECT study, which demonstrated significant benefits over standard care, including faster eschar removal and lower blood loss. NexoBrid is already approved in the EU and other markets. Vericel holds exclusive North American rights, with development support from BARDA.

Vericel Corporation (NASDAQ: VCEL) will present a company overview at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 12:30 PM Eastern Time. Nick Colangelo, the company's president and CEO, will be leading the presentation. A live webcast will be accessible on Vericel's Investor Relations website for those interested in learning more about the company's advancements in sports medicine and severe burn care. Vericel is recognized for its products, MACI® and Epicel®, and its license for NexoBrid®.